Alpha 2.0
Login Register
» Authors » S Luminari

S Luminari

Explore the profile of S Luminari including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 301
Followers 0
Related Specialties
Oncology
Hematology
General Surgery
Top 10 Co-Authors
M Federico
L Baldini
E Zucca
A Neri
F Merli
L Marcheselli
F Cavalli
M Ladetto
A J M Ferreri
G Gaidano
Published In
Ann Oncol
Ann Hematol
Leukemia
Blood
Mod Pathol
Affiliations
Soon will be listed here.
Recent Articles
1.
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047]
Kim T, Taszner M, Novelli S, Cho S, Villasboas J, Merli M, et al.
Ann Oncol . 2024 Dec; 36(3):352. PMID: 39627085
No abstract available.
2.
Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma
Kim T, Taszner M, Novelli S, Cho S, Villasboas J, Merli M, et al.
Ann Oncol . 2024 Aug; 35(11):1039-1047. PMID: 39147364
Background: Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple subtypes of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma. Patients...
3.
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
Ladetto M, Tavarozzi R, Zanni M, Evangelista A, Ferrero S, Tucci A, et al.
Ann Oncol . 2023 Nov; 35(1):118-129. PMID: 37922989
Background: Optimal consolidation for young patilents with relapsed/refractory (R/R) follicular lymphoma (FL) remains uncertain in the rituximab era, with an unclear benefit of autologous stem cell transplantation (ASCT). The multicenter,...
4.
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, et al.
Ann Oncol . 2017 Apr; 29(2):525. PMID: 28368466
No abstract available.
5.
ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia
Ladetto M, Buske C, Hutchings M, Dreyling M, Gaidano G, Le Gouill S, et al.
Ann Oncol . 2016 Oct; 27(12):2149-2160. PMID: 27701070
The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a...
6.
PO-03 - Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL)
Santi R, Ceccarelli M, Catania G, Monagheddu C, Evangelista A, Bernocco E, et al.
Thromb Res . 2016 May; 140 Suppl 1:S177. PMID: 27161692
Background: Recent studies show that the risk of VTE in NHL pts is similar to that observed in high risk solid tumors (i.e. pancreatic, ovarian cancer). VTE in NHL occurs...
7.
A diachronic-comparative analysis for the identification of the most powerful prognostic index for localized diffuse large B-cell lymphoma
Mian M, Marcheselli L, Rossi A, Visco C, Chiappella A, Volpetti S, et al.
Ann Oncol . 2014 Oct; 25(12):2398-2404. PMID: 25274614
Background: In the rituximab era, the conventional International Prognostic index (IPI) lost at least in part its predictive power, while the National Comprehensive Cancer Network-IPI (NCCN-IPI) seems to be a...
8.
Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
Arcaini L, Vallisa D, Rattotti S, Ferretti V, Ferreri A, Bernuzzi P, et al.
Ann Oncol . 2014 May; 25(7):1404-1410. PMID: 24799461
Background: Tumor regression after antiviral therapy (AT) is in favor of an etiological role of hepatitis C virus (HCV) in non-Hodgkin's B-cell lymphomas (NHL). Patients And Methods: We carried out...
9.
The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL)
Luminari S, Biasoli I, Versari A, Rattotti S, Bottelli C, Rusconi C, et al.
Ann Oncol . 2014 Jan; 25(2):442-7. PMID: 24412823
Background: [18F]fluorodeoxyglucose-positron emission tomography (PET) is emerging as a strong diagnostic and prognostic tool in follicular lymphoma (FL) patients. Patients And Methods: In a subset analysis of the FOLL05 trial...
10.
Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18 year follow-up of 488 patients (IELSG 23 study)
Mian M, Capello D, Ventre M, Grazio D, Svaldi M, Rossi A, et al.
Ann Hematol . 2013 Aug; 93(2):221-231. PMID: 23959436
It is known that extranodal head and neck diffuse large B cell lymphomas (eHN-DLBCL) can affect various anatomical structures what is not well-known, however, is whether they differ in terms...